Enfermedad hepática grasa relacionada a trastornos metabólicos actualización de conceptos y revisión bibliográ

Contenido principal del artículo

A. Fabrizzio Bardales Silva


Con el auge de los trastornos metabólicos, la enfermedad grasa hepática se proclama como la patología más frecuente que compromete al hígado a nivel mundial. Ante estas circunstancias, recientemente, se han renovado algunos conceptos y definicion e s en miras de comprender mejor este problema. Se destaca en la actualidad, la importancia de fenómenos como la resistencia a la insulina y otros mecanismos inflamatorios que favorecen a la degeneración grasa hepática y culminar en patologías tan graves como la cirrosis y el carcinoma hepático.


Los datos de descargas todavía no están disponibles.

Detalles del artículo

Cómo citar
Bardales Silva, A. F. (2022). Enfermedad hepática grasa relacionada a trastornos metabólicos: actualización de conceptos y revisión bibliográ. Revista Médica Basadrina, 15(4), 85–93. https://doi.org/10.33326/26176068.2021.4.1259
Artículo de revisión


Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed

disease. Mayo Clin Proc. 1980 Jul;55(7):434-8. DOI: https://doi.org/10.1086/412005

Zheng KI et al. From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chin Med J (Engl). 2020 Oct 5;133(19):2271- 2273. doi: 10.1097/CM9.0000000000000981 DOI: https://doi.org/10.1097/CM9.0000000000000981

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of pre valence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431 DOI: https://doi.org/10.1002/hep.28431

NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016 Apr 2; 387 (10026): 1377-1396. doi: 10.1016/S01406736(16)30054-X DOI: https://doi.org/10.1016/S0140-6736(16)30054-X

Younossi Z M, e t al. Nonalcoholic Steatohepatitis Is the Most R apidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021 Mar;19(3):580- 589.e5. doi: 10.1016/j.cgh.2020.05.064 DOI: https://doi.org/10.1016/j.cgh.2020.05.064

Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 May;158(7):1851- 1864. doi: 10.1053/j.gastro.2020.01.052. DOI: https://doi.org/10.1053/j.gastro.2020.01.052

Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease. Postgrad Med J. 2019 Jun; 95 (1124): 314-322. doi: 10.1136/postgradmedj-2018-136316 DOI: https://doi.org/10.1136/postgradmedj-2018-136316

Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 9 ; 313 (22): 22 63-7 3. Doi : 10.1001/jama.2015.5370 DOI: https://doi.org/10.1001/jama.2015.5370

Lin S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020 S ep;40(9):2082-2089. Doi: 10.1111/liv.14548 DOI: https://doi.org/10.1111/liv.14548

The Lancet Gastroenterology Hepatology. Redefining non-alcoholic fatty liver disease: what's in a name? Lancet Gastroenterol. Hepatol. 2020 May; 5 (5): 419. Doi:10.1016/S2468-1253(20)30091-1 DOI: https://doi.org/10.1016/S2468-1253(20)30091-1

Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consens us statement. J Hepatol. 2020 Jul;73(1):202-209. Doi: 10.1016/j.jhep.2020.03.039 DOI: https://doi.org/10.1016/j.jhep.2020.07.045

Ochiai Y, et al. Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease. Hepatol Res. 2021 Jan; 51 (1): 62-68. Doi: 10.1111/hepr.1357216. Kim SR, Kim KI. An Overview of NAFLD/NASH in Japan. Yakugaku Zasshi. 2016;136(4):565- 72. Japanese. doi: 10.1248/yakushi.15-00264-1

Tada T, et al. Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res. 2021 Aug;51(8):860-869. doi: 10.1111/hepr.13677 DOI: https://doi.org/10.1111/hepr.13677

Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res. 2021 Sep 2. doi: 10.1111/hepr.13706 DOI: https://doi.org/10.1111/hepr.13706

Roeb E, Geier A. Non alcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Z Gastroenterol. 2019 Apr;57(4):508-517. English. doi: 10.1055/a-0784-8827 DOI: https://doi.org/10.1055/a-0784-8827

Kim SR, Kim KI. An Overview of NAFLD/NASH in Japan. Yakugaku Zasshi. 2016;136(4):565-72. Japanese. doi: 10.1248/yakushi.15-00264-1 DOI: https://doi.org/10.1248/yakushi.15-00264-1

Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016 Aug;65(8):1017-25. Doi: 10.1016/j.metabol.2016.01.012 DOI: https://doi.org/10.1016/j.metabol.2016.01.012

Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014 May 14;15(5):8591-638. Doi: 10.3390/ijms15058591 DOI: https://doi.org/10.3390/ijms15058591

Parlati L, Régnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep. 2021 Aug 8 ; 3 (6): 100346. Doi: 10.1016/j.jhepr.2021.100346 DOI: https://doi.org/10.1016/j.jhepr.2021.100346

Sumida Y, Yoneda M. Current and future pharmaco logical the rapies for NAFLD/NASH. J Gastroenterol. 2018 Mar;53(3):362-376. Doi: 10.1007/s00535-017-1415-1 DOI: https://doi.org/10.1007/s00535-017-1415-1

Papatheodoridi M, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Curr Pharm Des.

; 24 (38): 4574-4586. Doi:10.2174/1381612825666190117102111 DOI: https://doi.org/10.2174/1381612825666190117102111

Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017 Nov;66(5):1486-1501. Doi: 10.1002/hep.29302 DOI: https://doi.org/10.1002/hep.29302

Paul S, Davis AM . Diagnosis and Management of Nonalcoholic Fatty Liver Disease. JAMA. 2018 Dec 18; 320(23): 2474-2475. Doi: 10.1001/jama.2018.17365 DOI: https://doi.org/10.1001/jama.2018.17365

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL- EASD - EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol. 2016 Jun; 64 (6): 1 388- 402. Doi:10.1016/j.jhep.2015.11.004 DOI: https://doi.org/10.1016/j.jhep.2015.11.004

Balakrishnan M, Loomba R. The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced

Fibrosis Among Patients With NAFLD. J Clin Gastroenterol. 2020 Feb;54(2):107-113. Doi: 10.1097/MCG.0000000000001284 DOI: https://doi.org/10.1097/MCG.0000000000001284

Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol. 2019 Mar 21; 25 (11): 1307-1326. doi: 10.3748/wjg.v25.i11.1307. PMID: 30918425 DOI: https://doi.org/10.3748/wjg.v25.i11.1307

Qureshi K, Neuschwander-Tetri BA. The molecular basis for current targets of NASH therapies. Expert Opin Investig Drugs. 2020 F e b ; 2 9 (2): 151 - 161. Doi: 10.1080/13543784.2020.1703949 DOI: https://doi.org/10.1080/13543784.2020.1703949

Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol. 2018. Feb; 68 (2): 238-250. Doi: 10.1016/j.jhep.2017.11.012 DOI: https://doi.org/10.1016/j.jhep.2017.11.012

Attia SL, Softic S, Mouzaki M. Evolving Role for Pharmacotherapy in NAFLD/NASH. Clin Transl Sci. 2021 Jan;14(1):11-19. Doi: DOI: https://doi.org/10.1111/cts.12839

1111/cts.1283931. Caldwell S. NASH Therapy : omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol. 2017 Jun;23(2):103-108. Doi: 10.3350/cmh.2017.0103

Mantovani A, Dalbeni A. NAFLD, MAFLD and DAFLD. Dig Liver Dis. 2020 Dec;52(12):1519-1520. Doi: 10.1016/j.dld.2020.09.013 DOI: https://doi.org/10.1016/j.dld.2020.09.013

Caldwell S. NASH Therapy : omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol. 2017 Jun;23(2):103-108. Doi: 10.3350/cmh.2017.0103 DOI: https://doi.org/10.3350/cmh.2017.0103

Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, Higuchi K. Metabolic Syndrome and Sarcopenia. Nutrients. 2021 Oct 7; 13 (10): 3519. Doi: 10.3390/nu13103519. PMID: 34684520. DOI: https://doi.org/10.3390/nu13103519